Tag:
UCB
Latest Headlines
Latest Headlines
UCB to set up major bioprocessing plant in Switzerland
Belgian biotech UCB says it's investing roughly $335 million in a 20,000-square-meter bioprocessing factory in the Swiss state of Fribourg that is expected to be among the largest in Europe at its
Euro-US hybrid Synosia lands $745M Parkinson's pact with UCB
Looking to beef up its pipeline for neurology drugs, Belgium's UCB has snagged the licensing rights to two experimental therapies from Synosia Therapeutics in a pact worth up to $745 million covering
UCB ups stake in oncology partner
UCB has upped its investment in Wilex, acquiring an additional 6.65 percent of the oncology company's shares to bring its total holdings to about 18 percent. Wilex acquired five oncology projects
UCB reformulating Parkinson's patch to eliminate crystals
Biopharma company UCB will reformulate its Parkinson's disease and restless leg syndrome drug Neupro before making it available on the U.S. market, per recommendation of the FDA. The regulator's
UCB sharpens axe for new round of job cuts
Belgium's UCB is reengineering some of its research operations as it trims two percent of its global workforce. Its research division NewMedicines is being downsized, with 174 positions at its
Sources: Abbott sparks Solvay bidding war, UCB may follow
The bidding for Solvay's pharma unit is heating up. Sources tell the Wall Street Journal that Abbott Laboratories has countered Nycomed's offer for the company. And UCB may be preparing to step in
New lupus trial success ignites Immunomedics shares
Just weeks after Human Genome Sciences grabbed everyone's attention with the first-ever successful Phase III trial for lupus, Immunomedics and UCB have now unveiled promising mid-stage data for their
UCB shares jump on FDA's approval of Cimzia
Shares of Belgium's UCB shot up after the company announced that the FDA had approved its blockbuster rheumatoid arthritis drug Cimzia. The drug, which the patient can inject himself using a
FDA announces several approvals
It's a busy Monday morning at the FDA as the agency announced several approvals. Here's the run-down:
The FDA has approved Pfizer and UCB's Toviaz extended-release tablets for the treatment of
Pfizer, UCB, UK create tech company to speed R&D
Pfizer and UCB have joined forces to launch Cyclofluidic, which they describe as a "breakthrough technology company established with the aim of significantly accelerating the drug discovery process
